Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 66
Filtrar
1.
Urologiia ; (1): 41-48, 2024 Mar.
Artigo em Russo | MEDLINE | ID: mdl-38650405

RESUMO

PURPOSE: dentification of bioimpedance and clinical features in young men with chronic pelvic pain inflammatory syndrome (CP/CPPS NIH IIIa) depending on the somatotype. METHOD: s. 150 men of the first period of adulthood from 22 to 35 years old with CP/CPPS NIH IIIa were examined from 2018 to 2022 years. The average age was 31 [28; 34] year. Somatotypes were computed according to Carter and Heath. Body composition was assessed anthropometry and bioimpedance analysis. RESULTS: Ectomorphs had the least clinical, laboratory and instrumental manifestations of CP/CPPS NIH IIIa, the levels of total and free testosterone were the highest. The active cell mass predominated in the component composition of the body. Manifestations in mesomorphs had a moderate degree of severity. Endomorphs had the most severe manifestations of CP/CPPS NIH IIIa, the largest amount of fat mass was noted in the body composition than in men of other somatotypes, the hormonal status was characterized by the lowest levels of free and total testosterone, and the highest level of estradiol. DISCUSSION: Based on the literature data and our own results, it can be assumed that the identified changes in the body component composition and hormonal status of men contribute to the maintenance of chronic inflammation in the prostate, organ ischemia, impaired intracranial metabolism, recurrent course of CP/CPPS NIH IIIa, which significantly reduces the patients quality of life and increases the risk of prostate inflammation with age. CONCLUSION: Determining the somatotype and conducting a component analysis of body composition allows patients to be divided into groups according to the severity of manifestations of CP/CPPS NIH IIIa. The revealed patterns allow us to classify male endomorphs into the group with the most severe manifestations of CP/CPPS NIH IIIa.


Assuntos
Composição Corporal , Dor Pélvica , Prostatite , Somatotipos , Humanos , Masculino , Prostatite/metabolismo , Prostatite/sangue , Prostatite/complicações , Prostatite/patologia , Adulto , Dor Pélvica/sangue , Dor Pélvica/etiologia , Dor Pélvica/metabolismo , Adulto Jovem , Testosterona/sangue , Dor Crônica/sangue , Dor Crônica/etiologia
2.
BMC Womens Health ; 24(1): 257, 2024 Apr 24.
Artigo em Inglês | MEDLINE | ID: mdl-38658933

RESUMO

BACKGROUND AND OBJECTIVE: Endometriosis (EM) involves the peripheral nervous system and causes chronic pain. Sensory nerves innervating endometriotic lesions contribute to chronic pain and influence the growth phenotype by releasing neurotrophic factors and interacting with nearby immune cells. Calcitonin gene-related peptide (CGRP), a pain-signaling neurotransmitter, has a significant role. This study examines the effect of Dienogest (DNG), a hormone therapy used for managing EM -related pain, on serum CGRP levels in EM patients. MATERIALS AND METHODS: The Visual Analog Scale (VAS) assessed pain in diagnosed EM. INDIVIDUALS: Serum samples were obtained to measure CGRP concentration. Participants received a 2 mg/day oral dose of DNG for six months as prescribed treatment. Additional serum samples were collected after this period to measure CGRP levels. RESULTS: In the EM group, 6.7%, 33.3%, and 20% had ovarian EM, ovarian plus uterosacral, and ovarian plus bladder, respectively. The EM group showed higher CGRP serum levels than the control group (80.53 ± 16.13 vs. 58.55 ± 6.93, P < 0.0001). Still, after drug administration, CGRP serum levels significantly decreased compared to pre-treatment levels (69.66 ± 11.53 vs. 80.53 ± 16.13, P < 0.05). The EM group showed higher pain compared to the control group (7.93 ± 1.58 vs. 0.13 ± 0.35, P < 0.0001), but after drug administration, pain significantly decreased compared to pre-treatment levels (1.00 ± 2.00 vs. 7.93 ± 1.58, P < 0.05). CONCLUSION: DNG administration reduces pain and serum CGRP levels in EM patients, offering the potential for innovative treatments and tailored options. Understanding neurotransmitter roles and drug effects can aid in discovering more effective modulators for these pathways.


Assuntos
Peptídeo Relacionado com Gene de Calcitonina , Endometriose , Nandrolona , Nandrolona/análogos & derivados , Dor Pélvica , Humanos , Feminino , Endometriose/tratamento farmacológico , Endometriose/complicações , Endometriose/sangue , Nandrolona/uso terapêutico , Nandrolona/administração & dosagem , Adulto , Peptídeo Relacionado com Gene de Calcitonina/sangue , Dor Pélvica/tratamento farmacológico , Dor Pélvica/etiologia , Dor Pélvica/sangue , Medição da Dor , Dor Crônica/tratamento farmacológico , Dor Crônica/etiologia , Adulto Jovem
3.
Reprod Sci ; 28(12): 3480-3490, 2021 12.
Artigo em Inglês | MEDLINE | ID: mdl-34524640

RESUMO

Endometriosis is a common, chronic inflammatory condition, thought to have a higher incidence in symptomatic women, yet, commonly associated symptoms do not always correlate with the presence or severity of disease and diagnosis requires surgery. We prospectively collected data and assessed symptomology and NMR spectroscopy-based metabolomics of 102 women undergoing laparoscopic sterilisation at a tertiary referral centre in a cross-sectional study. Twelve women were incidentally diagnosed with endometriosis (11.7%). According to the pre-operative questionnaire, presence and absence of many symptoms usually attributed to endometriosis were declared at similar frequencies in women with or without endometriosis. Women with endometriosis reported apparently more persistent heavy periods (50% vs 18.9%), prolonged periods (25% versus 7.8%) and problems conceiving (27.3% versus 9%) than those without endometriosis. NMR could not discern any distinguishable differences in the serum metabolome between those with and without endometriosis. Our paper highlights the complex symptomology experienced by women, regardless of a surgical diagnosis of endometriosis. Previous literature and the current study failed to identify clear, distinguishable symptoms or biomarkers pertinent to surgically confirmed endometriosis in the general population. Therefore, development of effective, non-invasive tests for identifying this heterogenous benign condition, endometriosis, is likely to be challenging.


Assuntos
Endometriose/sangue , Endometriose/diagnóstico , Laparoscopia/métodos , Espectroscopia de Ressonância Magnética/métodos , Metabolômica/métodos , Esterilização Reprodutiva/métodos , Adulto , Biomarcadores/sangue , Estudos de Coortes , Estudos Transversais , Feminino , Humanos , Pessoa de Meia-Idade , Dor Pélvica/sangue , Dor Pélvica/diagnóstico , Valor Preditivo dos Testes , Estudos Prospectivos , Inquéritos e Questionários , Adulto Jovem
4.
Oxid Med Cell Longev ; 2021: 6687493, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33815658

RESUMO

Mechanisms of the brain-related comorbidities in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) are still largely unknown, although CP/CPPS is one of the major urological problems in middle-aged men, while these neuropsychological incapacities considerably diminish life quality. The objectives of this study were to assess behavioral patterns in rats with CP/CPPS and to determine whether these patterns depend on alterations in the brain oxidative stress, corticosterone, and hippocampal parvalbumin-positive (PV+) interneurons. Adult male Wistar albino rats from CP/CPPS (intraprostatic injection of 3% λ-carrageenan, day 0) and sham (0.9% NaCl) groups were subjected to pain and anxiety-like behavior tests (days 2, 3, and 7). Afterwards, rats were sacrificed and biochemical and immunohistochemical analyses were performed. Scrotal allodynia and prostatitis were proven in CP/CPPS, but not in sham rats. Ethological tests (open field, elevated plus maze, and light/dark tests) revealed significantly increased anxiety-like behavior in rats with CP/CPPS comparing to their sham-operated mates starting from day 3, and there were significant intercorrelations among parameters of these tests. Increased oxidative stress in the hippocampus, thalamus, and cerebral cortex, as well as increased serum corticosterone levels and decreased number of hippocampal PV+ neurons, was shown in CP/CPPS rats, compared to sham rats. Increased anxiety-like behavior in CP/CPPS rats was significantly correlated with these brain biochemical and hippocampal immunohistochemical alterations. Therefore, the potential mechanisms of observed behavioral alterations in CP/CPPS rats could be the result of an interplay between increased brain oxidative stress, elevated serum corticosterone level, and loss of hippocampal PV+ interneurons.


Assuntos
Ansiedade/sangue , Comportamento Animal , Encéfalo/patologia , Corticosterona/sangue , Interneurônios/metabolismo , Estresse Oxidativo , Dor Pélvica/sangue , Prostatite/sangue , Animais , Dor Crônica/sangue , Dor Crônica/fisiopatologia , Teste de Labirinto em Cruz Elevado , Hipocampo , Masculino , Atividade Motora , Limiar da Dor , Parvalbuminas/metabolismo , Próstata/patologia , Prostatite/fisiopatologia , Ratos Wistar , Síndrome
5.
Cells ; 10(3)2021 02 25.
Artigo em Inglês | MEDLINE | ID: mdl-33668701

RESUMO

Altered immune mechanisms are implicated in the pathogenesis of endometriosis. CTLA-4 is a membrane receptor that favors the anergic state of lymphocytes, which may disrupt the immune system response in the endometriotic environment. In this study, we examined the expression of CTLA-4 on T and B cells by flow cytometry and its levels in blood serum and peritoneal fluid by ELISA. Levels of CTLA-4+ T cells were significantly higher in patients with more advanced endometriosis than in those with less advanced disease. Additionally, the negative correlation of CTLA-4+ T lymphocytes and the percentage of NK and NKT-like cells in women with endometriosis and infertility may indicate a different etiopathogenesis of endometriosis accompanying infertility. Our findings shed light on the potential of CTLA-4 in developing new diagnostic and therapeutic approaches in endometriosis management.


Assuntos
Antígeno CTLA-4/metabolismo , Endometriose/metabolismo , Infertilidade/metabolismo , Inflamação/metabolismo , Adulto , Antígenos CD19/metabolismo , Líquido Ascítico/metabolismo , Linfócitos B/imunologia , Linfócitos T CD4-Positivos/imunologia , Linfócitos T CD8-Positivos/imunologia , Antígeno CTLA-4/sangue , Estudos de Casos e Controles , Doença Crônica , Endometriose/sangue , Endometriose/imunologia , Feminino , Humanos , Infertilidade/sangue , Infertilidade/imunologia , Inflamação/sangue , Inflamação/imunologia , Pessoa de Meia-Idade , Dor Pélvica/sangue , Dor Pélvica/complicações , Dor Pélvica/imunologia , Solubilidade , Linfócitos T/imunologia , Adulto Jovem
6.
J Musculoskelet Neuronal Interact ; 21(1): 121-129, 2021 03 01.
Artigo em Inglês | MEDLINE | ID: mdl-33657762

RESUMO

OBJECTIVES: To determine the effect of neurogenic acupoint dry cupping therapy on high sensitive C-reactive protein (hs-CRP) level, pain perception & intensity, and life impact of pelvic pain in women with chronic pelvic pain (CPP), with regard to the biological and neurophysiological impacts of dry cupping on acupoint. METHODS: Thirty women with CPP were randomly divided into two equal groups; the study group received dry cupping on neurogenic acupoints plus lifestyle modifications for 8 weeks (n=15), while the control group received only lifestyle modifications for 8 weeks (n=15). Women were assessed pre- and post-rehabilitation program with the hs-CRP blood test, the short-form McGill Pain Questionnaire (SF-MPQ), and the pelvic pain impact questionnaire (PPIQ). RESULTS: Comparing both groups post-treatment revealed that there were significant reductions in levels of hs-CRP, and scores of SF-MPQ & PPIQ (p<0.05) in the study group compared with the control group. Also, there were significant positive correlations between hs-CRP and both SF-MPQ "Visual Analogue Scale (VAS), Present Pain Intensity (PPI) index & Pain Rating Index (PRI)" and PPIQ (p<0.05). CONCLUSION: Neurogenic acupoint cupping therapy had significantly improving effects on the degree of inflammation, pain perception & intensity, and life impact of pelvic pain in women with CPP.


Assuntos
Pontos de Acupuntura , Proteína C-Reativa/metabolismo , Dor Crônica/sangue , Ventosaterapia/métodos , Percepção da Dor/fisiologia , Dor Pélvica/sangue , Adulto , Dor Crônica/psicologia , Dor Crônica/terapia , Ventosaterapia/psicologia , Feminino , Humanos , Medição da Dor/métodos , Medição da Dor/psicologia , Dor Pélvica/psicologia , Dor Pélvica/terapia , Estudos Prospectivos , Comportamento de Redução do Risco , Resultado do Tratamento
7.
J Gynecol Obstet Hum Reprod ; 50(5): 102094, 2021 May.
Artigo em Inglês | MEDLINE | ID: mdl-33601074

RESUMO

OBJECTIVE: To analyze the predictive value of neutrophils, lymphocytes, platelets, neutrophils to lymphocytes ratio (NLR), platelets to lymphocytes ratio (PLR) in identifying the occurrence of post-embolization syndrome (PES) after uterine artery embolization (UAE). METHODS: We conducted a retrospective observational study in a single tertiary care center located in New York City during period of November 2014 - December 2018, for patients who underwent UAE. PES was defined as the occurrence of pelvic pain, nausea or fever within one week after the procedure. RESULTS: We enrolled 62 patients: 12 of them had PES and 50 served as controls. Platelets were statistically significantly higher in patients with PES (p=0.036). Specifically, a platelet count greater than 336×103/uL was identified as cut-off with a specificity of 91.8 %, a sensitivity of 33.3 %, a positive predictive value of 46 % and a negative predictive value of 85 %. The area under the curve (AUC) was 0.721 (CI 0.536-0.907). CONCLUSION: Patients with a preprocedural platelet count less than 336×103/uL were less likely to have PES. If confirmed by larger studies, the platelet count could be incorporated into patient counseling and preoperative algorithms to identify the ideal UAE candidates.


Assuntos
Febre/sangue , Náusea/sangue , Dor Pélvica/sangue , Contagem de Plaquetas , Embolização da Artéria Uterina/efeitos adversos , Adulto , Algoritmos , Área Sob a Curva , Feminino , Febre/etiologia , Humanos , Contagem de Leucócitos , Contagem de Linfócitos , Pessoa de Meia-Idade , Náusea/etiologia , Neutrófilos/citologia , Dor Pélvica/etiologia , Valor Preditivo dos Testes , Estudos Retrospectivos , Sensibilidade e Especificidade , Síndrome
8.
Inflammation ; 44(1): 243-248, 2021 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-32827084

RESUMO

Chronic prostatitis/chronic pelvic pain syndromes (CP/CPPS) is a clinical tricky problem due to its enigmatic etiology, low cure rate, and high recurrence rate. The research on its pathogenesis has never stopped. In this experimental autoimmune prostatitis (EAP) model, male C57BL/6 mice were subcutaneously immunized with prostate extracts in an adequate adjuvant. For mice in the antibody intervention group, anti-T2 polyclonal antibodies were intraperitoneally injected during the induction of EAP. Animals were periodically monitored for pelvic pain. Hematoxylin and eosin staining was used to assess prostate inflammation. Tumor necrosis factor-α (TNF-α) levels in serum were measured by ELISA kits. The immunized animals developed prostatitis as a consequence of the immune response against prostate antigens. Pelvic pain thresholds were gradually decreased and TNF-α expression significantly increased. T2 plays an important role in the disease since polyclonal antibodies to T2 greatly ameliorated symptoms in animals induced for EAP. T2 peptide may represent the major autoantigen epitope in EAP, which could serve for a better understanding of the etiology of CP/CPPS.


Assuntos
Autoantígenos/sangue , Doenças Autoimunes/sangue , Epitopos/sangue , Dor Pélvica/sangue , Fragmentos de Peptídeos/antagonistas & inibidores , Prostatite/sangue , Sequência de Aminoácidos , Animais , Autoantígenos/imunologia , Doenças Autoimunes/imunologia , Doenças Autoimunes/prevenção & controle , Epitopos/imunologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Dor Pélvica/imunologia , Dor Pélvica/prevenção & controle , Fragmentos de Peptídeos/sangue , Fragmentos de Peptídeos/imunologia , Prostatite/imunologia , Prostatite/prevenção & controle , Coelhos
9.
Gynecol Endocrinol ; 36(sup1): 16-19, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-33305665

RESUMO

OBJECTIVE: Genital endometriosis (GE) is a widespread gynecological disease which requires its further pathogenesis investigation and search for new effective treatments. The known data of oxytocin receptor presence in endometrioid heterotopy smooth muscle cells give some grounds to assume oxytocin participation in the pathogenesis of endometriosis. The present study objective was to evaluate oxytocin level in peripheral blood (PB) in patients with endometriosis associated pain syndrome and to estimate the efficacy of oxytocin receptor inhibitors (IOXTR) administration based on animal endometriosis model. MATERIALS AND METHODS: The basic group comprised 61 patients with endometriosis associated pain syndrome, while 21 patients formed the control group. VAS, MPQ, and BBS objective tests were applied for pain syndrome evaluation. Oxytocin level in PB was measured by immunoenzyme method. After confirmation of endometriosis experimental model formation in rats and further randomization, a daily IOXTR intra-abdominal injection was performed in a dose of 0.35 mg/kg/24 h in the basic group (n = 12) or saline solution administration in the control (n = 12). On the final stage, endometrioid heterotopy size measuring was performed along with histological examination. RESULTS: Oxytocin level in PB was authentically higher in patients with GE compared to the control: 51.45 (35.54-62.76) pg/mL and 27.64 (23.23-34.12) pg/mL, respectively (p<.001). Positive correlation between oxytocin PB level and pain syndrome expression was established in patients with GE: VAS (r = 0.76; p<.001), MPQ (r = 0.52; p<.001), and BBS (r = 0.57; p<.001). Based on the experimental disease model authentical decrease of endometrioid heterotopy average area was observed after IOXTR therapy compared to the control (7.3 ± 1.8 mm2 and 22.2 ± 1.2 mm2, respectively, p<.05). CONCLUSIONS: The obtained results confirm the oxytocin role in the pathogenesis of endometrioid associated pain syndrome. The high efficacy of IOXTR administration based on animal model of surgically induced endometriosis allows viewing this method as a perspective therapy.


Assuntos
Endometriose/tratamento farmacológico , Doenças Peritoneais/tratamento farmacológico , Receptores de Ocitocina/antagonistas & inibidores , Vasotocina/análogos & derivados , Adolescente , Adulto , Animais , Estudos de Casos e Controles , Modelos Animais de Doenças , Avaliação Pré-Clínica de Medicamentos , Endometriose/sangue , Endometriose/complicações , Endometriose/patologia , Feminino , Humanos , Pessoa de Meia-Idade , Terapia de Alvo Molecular/métodos , Terapia de Alvo Molecular/tendências , Ocitocina/análogos & derivados , Ocitocina/sangue , Dor Pélvica/sangue , Dor Pélvica/tratamento farmacológico , Dor Pélvica/etiologia , Dor Pélvica/patologia , Doenças Peritoneais/sangue , Doenças Peritoneais/complicações , Doenças Peritoneais/patologia , Ratos , Ratos Wistar , Síndrome , Vasotocina/uso terapêutico , Adulto Jovem
10.
BMC Womens Health ; 20(1): 189, 2020 09 03.
Artigo em Inglês | MEDLINE | ID: mdl-32883256

RESUMO

BACKGROUND: Endometriosis is a long-standing progressive disease that affects women of reproductive age. Macrophage migration inhibitory factor (MIF) is one of non-invasive blood biomarker that was detected in sera of endometriotic patients. The present study aimed to determine the accuracy of serum MIF in diagnosing endometriosis in women with infertility and chronic pelvic pain, and correlate its level to the stage of the disease. METHODS: Observational case-control study conducted at Fayoum University hospital from March 2016 till September 2018. Three hundred women candidate for diagnostic laparoscopy for either infertility or gynecologic chronic pelvic pain were included. The study group included patients with symptoms suggestive of endometriosis or chocolate cyst by ultrasound and proved by laparoscopy and histopathology. The control group included other causes of infertility or pelvic pain. All patients undergone either diagnostic or operative laparoscopy, and before laparoscopy blood sampling for quantitative measurement of macrophage migration inhibitory factor (MIF) protein in serum by ELISA technique. RESULTS: The level of serum MIF was significantly higher in endometriosis group compared to control group (1.75 ± 1.48 pg/ml and 0.51 ± 0.45 pg/ ml, respectively, P = < 0.001), with a progressive increase with advancing stage (stage I, 1.3 ± 1.03 pg/ml, stage II, 1.7 ± 1.57 pg/ml, stage III, 2.1 ± 1.19 pg/ml and in stage IV, 3.2 ± 2.6 pg/ml). Moreover, in patients presented with pain and infertile patients showed significantly higher levels of serum MIF (1.92 ± 1.13 vs 1.21 ± 1.17 and 1.82 ± 1.13 vs 1.32 ± 0.91 respectively with p-value < 0.001). ROC curve of serum MIF with a cut off value of 0.85 pg/ml or more achieves a sensitivity of 80.6%, specificity of 83.3%, positive predictive value of 82.9% and negative predictive value of 81.2%. CONCLUSION: Serum MIF might be a promising marker not only for noninvasive diagnosis of endometriosis but as a target for detecting severity as well.


Assuntos
Endometriose/diagnóstico , Endométrio/diagnóstico por imagem , Infertilidade Feminina/complicações , Fatores Inibidores da Migração de Macrófagos/sangue , Dor Pélvica/etiologia , Adulto , Biomarcadores/sangue , Estudos de Casos e Controles , Endometriose/sangue , Endometriose/imunologia , Endométrio/metabolismo , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Infertilidade Feminina/sangue , Infertilidade Feminina/imunologia , Laparoscopia , Dor Pélvica/sangue , Dor Pélvica/imunologia
11.
Reprod Sci ; 27(10): 1839-1847, 2020 10.
Artigo em Inglês | MEDLINE | ID: mdl-32572832

RESUMO

Some chronic pain conditions and comorbidities suppress the hypothalamic-pituitary-adrenal (HPA) axis and response to dynamic testing. We measured HPA axis responses to corticotropin-releasing hormone (CRH) administration in relation to chronic pelvic pain and endometriosis. In a cross-sectional study of women (n = 54) with endometriosis-associated chronic pelvic pain (n = 22), chronic pelvic pain alone (n = 12), or healthy volunteers (n = 20), adrenocorticotropic-releasing hormone (ACTH) and cortisol levels were measured at 0, 15, 30, and 45 min after intravenous ovine CRH administration. ACTH and cortisol delta (peak-baseline) and area under the curve (AUC) were compared by study group and assessed for association with race and menstrual and non-menstrual pain severity. HPA axis responses did not differ among the racially diverse groups or in those with pain compared with healthy volunteers. However, when stratified by race, ACTH delta (129.9 ± 130.7 vs. 52.5 ± 66.0 pg/mL; p = 0.003), ACTH AUC (4813 ± 4707 vs. 2290 ± 2900 min*pg/mL; p = 0.013), and cortisol delta (26.3 ± 21.5 vs. 13.2 ± 9.7 µg/mL; p = 0.005) were significantly higher in black (n = 10) than predominately white (non-black) subjects (n = 44; 39/44 white). In analyses among primarily white (non-black) women, greater menstrual pain severity was associated with blunted ACTH delta (p = 0.015) and cortisol delta (p = 0.023), and greater non-menstrual pain severity with blunted cortisol delta (p = 0.017). Neuroendocrine abnormalities in women with chronic pelvic pain may differ by pain manifestations and may vary by race. The higher HPA axis response in black women merits investigation in pelvic pain studies stratified by race. In white (non-black) women experiencing pain, a blunted response was related to pain severity suggesting pain affects women independently of endometriosis lesions.


Assuntos
Hormônio Adrenocorticotrópico/sangue , Dor Crônica/sangue , Endometriose/sangue , Hidrocortisona/sangue , Sistema Hipotálamo-Hipofisário/fisiopatologia , Dor Pélvica/sangue , Sistema Hipófise-Suprarrenal/fisiopatologia , Adulto , Dor Crônica/etiologia , Dor Crônica/fisiopatologia , Hormônio Liberador da Corticotropina/farmacologia , Estudos Transversais , Endometriose/complicações , Endometriose/fisiopatologia , Feminino , Humanos , Sistema Hipotálamo-Hipofisário/efeitos dos fármacos , Pessoa de Meia-Idade , Dor Pélvica/etiologia , Dor Pélvica/fisiopatologia , Sistema Hipófise-Suprarrenal/efeitos dos fármacos , Adulto Jovem
12.
J Obstet Gynaecol ; 40(4): 520-525, 2020 May.
Artigo em Inglês | MEDLINE | ID: mdl-31455176

RESUMO

The aim of this study was to evaluate whether balneotherapy might be effective in patients with chronic pelvic pain (CPP) in the short term. This was an open and prospective pilot study. The balneotherapy programme was performed in a spa resort located in Wando Island, Republic of Korea from August 26 2018 to September 1 2018. It consisted of 10 heated seawater baths (38 °C, 20 minutes) and 10 mud-pack applications (40 °C, 10 minutes) for five days. Sixteen patients were enrolled. Upon analysing responses from a patient questionnaire, we found improvement in parameters such as pain, bladder irrigation symptoms and quality of life after balneotherapy. Inflammatory marker IL-1 and TNF-α was significantly decreased after treatment compared to baseline. There were no adverse events during treatment. Our data suggest that five-day balneotherapy can be beneficial for patients with CPP in the short term.Impact statementWhat is already known on this subject? The majority of articles in the field of balneotherapy discuss the treatment of rheumatic or dermatological disease. However, data on the effectiveness of balneotherapy for chronic pelvic pain are very limited.What the results of this study add? Our study suggests that balneotherapy can be beneficial for patients with CPP in the short-term. The duration of balneotherapy was five days, which is shorter than that of the European studies. Intuitively, it may be doubtful whether short-term therapy has any practical effect. As most people living in Korea have a vacation period of about one week each in summer and winter, the choice of a five-day programme in our study reflects the reality of vacation schedules.What the implications are of these findings for clinical practice and/or further research? Further studies are necessary to demonstrate the persistence of these benefits on the long term, as well as their existence in appropriate control group and different duration of treatment.


Assuntos
Balneologia/métodos , Peloterapia/métodos , Dor Pélvica , Qualidade de Vida , Irrigação Terapêutica/métodos , Dor Crônica , Duração da Terapia , Feminino , Humanos , Interleucina-1/sangue , Masculino , Pessoa de Meia-Idade , Medição da Dor/métodos , Dor Pélvica/sangue , Dor Pélvica/etiologia , Dor Pélvica/psicologia , Dor Pélvica/terapia , Projetos Piloto , Estudos Prospectivos , República da Coreia/epidemiologia , Resultado do Tratamento , Fator de Necrose Tumoral alfa/sangue
13.
J Sex Med ; 16(6): 763-766, 2019 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-31010782

RESUMO

BACKGROUND: Vaginal diazepam is frequently used to treat pelvic floor tension myalgia and pelvic pain despite limited knowledge of systemic absorption. AIM: To determine the pharmacokinetic and adverse event profile of diazepam vaginal suppositories. METHODS: We used a prospective pharmacokinetic design with repeated assessments of diazepam levels. Eight healthy volunteers were administered a 10-mg compounded vaginal diazepam suppository in the outpatient gynecologic clinic. Serum samples were collected at 0, 45, 90, 120, and 180 minutes; 8, 24, and 72 hours; and 1 week following administration of a 10-mg vaginal suppository. The occurrence of adverse events was assessed using the alternate step and tandem walk tests, the Brief Confusion Assessment Method, and numerical ratings. Plasma concentrations of diazepam and active long-acting metabolites were measured. Pharmacokinetic parameters were calculated by standard noncompartmental methods. RESULTS: The mean peak diazepam concentration (Cmax) of 31.0 ng/mL was detected at a mean time (Tmax) of 3.1 hours after suppository placement. The bioavailability was found to be 70.5%, and the mean terminal elimination half-life was 82 hours. The plasma levels of temazepam and nordiazepam peaked at 0.8 ng/mL at 29 hours and 6.4 ng/mL at 132 hours, respectively. Fatigue was reported by 3 of 8 participants. CLINICAL IMPLICATIONS: Serum plasma concentrations of vaginally administered diazepam are low; however the half-life is prolonged. STRENGTHS & LIMITATIONS: Strengths include use of inclusion and exclusion criteria aimed at mitigating clinical factors that could adversely impact diazepam absorption and metabolism, and the use of an ultrasensitive LC-MS/MS assay. Limitations included the lack of addressing the efficacy of vaginal diazepam in lieu of performing a pure pharmacokinetic study with healthy participants. CONCLUSION: Vaginal administration of diazepam results in lower peak serum plasma concentration, longer time to peak concentration, and lower bioavailability than standard oral use. Providers should be aware that with diazepam's long half-life, accumulating levels would occur with chronic daily doses, and steady-state levels would not be reached for up to 1 week. This profile would favor intermittent use to allow participation in physical therapy and intimacy. Larish AM, Dickson RR, Kudgus RA, et al. Vaginal Diazepam for Nonrelaxing Pelvic Floor Dysfunction: The Pharmacokinetic Profile. J Sex Med 2019;16;763-766.


Assuntos
Diazepam/farmacocinética , Relaxantes Musculares Centrais/farmacocinética , Distúrbios do Assoalho Pélvico/tratamento farmacológico , Administração Intravaginal , Administração Oral , Adulto , Cromatografia Líquida , Dor Crônica/sangue , Dor Crônica/tratamento farmacológico , Diazepam/administração & dosagem , Dispareunia/sangue , Dispareunia/tratamento farmacológico , Feminino , Meia-Vida , Voluntários Saudáveis , Humanos , Masculino , Relaxantes Musculares Centrais/administração & dosagem , Mialgia/sangue , Mialgia/tratamento farmacológico , Diafragma da Pelve , Distúrbios do Assoalho Pélvico/sangue , Dor Pélvica/sangue , Dor Pélvica/tratamento farmacológico , Estudos Prospectivos , Supositórios , Espectrometria de Massas em Tandem , Adulto Jovem
14.
Andrologia ; 51(2): e13187, 2019 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-30357879

RESUMO

We investigated the clinical characteristics of patients with varicocele according to the presence or absence of scrotal pain. We retrospectively reviewed the records of patients who underwent varicocelectomy. The age, body mass index, grade, laterality of varicocele, testicular volume difference, time to hospital visit, serum testosterone level and semen parameters were evaluated. A total of 954 patients were included. The painful group had lower mean age, lower BMI, higher grade of varicocele, smaller testicular volume difference and shorter time to hospital visit than the painless group. In addition, the median serum total testosterone level and total sperm count, concentration and motility were higher in the painful group than in the painless group. In multivariate analysis, there were significant differences between the two groups in age, grade of varicocele, testis volume difference, time to hospital visit, total sperm count and concentration. Patients with painful varicocele visited hospital earlier because of the pain and tended to start treatment sooner. They were also younger, had smaller testis atrophy and had higher sperm concentration, even though they had a higher grade of varicocele than patients without pain. Although scrotal pain in varicocele patients is difficult to treat, it leads to early diagnosis and treatment.


Assuntos
Dor Pélvica/diagnóstico , Motilidade dos Espermatozoides/fisiologia , Testosterona/sangue , Varicocele/complicações , Adolescente , Adulto , Índice de Massa Corporal , Humanos , Masculino , Medição da Dor , Dor Pélvica/sangue , Dor Pélvica/etiologia , Estudos Retrospectivos , Análise do Sêmen , Contagem de Espermatozoides , Avaliação de Sintomas , Varicocele/sangue , Adulto Jovem
15.
Eur J Contracept Reprod Health Care ; 23(5): 344-350, 2018 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-30372645

RESUMO

OBJECTIVE: The aim of the study was to assess the serum levels of the following biomarkers in women with endometriosis-associated pelvic pain before and after six months of using the etonogestrel (ENG) contraceptive implant or the 52 mg levonorgestrel-releasing intrauterine system (LNG-IUS): cancer antigen (CA)-125, cluster of differentiation (CD) 23 and endometrial nerve fibre density. METHODS: The study was conducted at the Department of Obstetrics and Gynaecology, University of Campinas Medical School, Brazil. A total of 103 women with endometriosis-associated pain diagnosed by surgery, transvaginal ultrasound and/or magnetic resonance imaging were included. Endometrial nerve fibre density and serum levels of CA-125 and soluble CD23 were assessed before and after six months of using the allocated method and were correlated to 10 cm visual analogue scale (VAS) scores for non-cyclical pelvic pain and dysmenorrhoea. RESULTS: Both contraceptive methods significantly reduced concentrations of serum soluble CD23 and endometrial nerve fibre density (p < .001); however, CA-125 was significantly reduced only among users of the ENG implant (p < .05). No correlation was observed between reduction of biomarkers and improvement of VAS pain and dysmenorrhoea scores. No differences were observed between the ENG implant and the LNG-IUS. CONCLUSION: Both progestin-only contraceptives significantly reduced two out of the three biomarkers evaluated. These two biomarkers could, therefore, be used as surrogate markers to follow up medical treatment of endometriosis-associated pain.


Assuntos
Anticoncepcionais Femininos/administração & dosagem , Desogestrel/administração & dosagem , Endometriose/sangue , Levanogestrel/administração & dosagem , Dor Pélvica/sangue , Adulto , Biomarcadores/sangue , Brasil , Antígeno Ca-125/sangue , Implantes de Medicamento/administração & dosagem , Endometriose/complicações , Endometriose/tratamento farmacológico , Endométrio/inervação , Feminino , Humanos , Dispositivos Intrauterinos Medicados , Fibras Nervosas/patologia , Dor Pélvica/etiologia , Receptores de IgE/sangue , Resultado do Tratamento
16.
Int Urol Nephrol ; 50(3): 395-399, 2018 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-29235061

RESUMO

PURPOSE: Immune mechanisms have been hypothesized to contribute to the development of CP/CPPS. In this study, we investigated the differential expression of immune factors between patients with CP/CPPS and healthy volunteers. METHODS: This study was registered in Australian New Zealand Clinical Trials Registry. Healthy volunteers and patients with CP/CPPS were enrolled in this study. The inclusion criteria for patients were below: (1) aged 18-45 years old; (2) prostatitis-related syndrome longer than 3 months; (3) normal routine urine culture and negative bacterial culture in prostatic fluid. Patients were further classified into two groups: types IIIA and IIIB CP/CPPS according to the results of EPS routine test. Serum immune markers include IgA, IgM, IgG, CD4+ and CD8+. RESULTS: There are total 23 CP/CPPS patients, including 12 type IIIB and 11 type IIIA. Relatively, there are 26 healthy volunteers. The serum levels of IgG were higher in CP/CPPS patients compared to healthy volunteers (1141.2 ± 204.3 vs 1031.9 ± 173.7 mg/L, p = 0.045), while the serum levels of CD8+ were lower in CP/CPPS patients compared to healthy volunteers (492.8 ± 185.6 vs 640.0 ± 246.8 cells/µL, p = 0.021). Furthermore, serum levels of IgG were higher in patients with IIIA CP/CPPS compared to those with IIIB (1244.3 ± 151.6 vs 1054.3 ± 209.3 mg/L, p = 0.023). CONCLUSIONS: Differential levels of IgG and CD8+ between CPPS patients and healthy volunteers suggest a contributing role of immune mechanisms to the development of CP/CPPS; and IgG may play an important role in inflammatory CPPS. Clinical Study registration number ACTRN12613000792729.


Assuntos
Contagem de Linfócito CD4 , Linfócitos T CD8-Positivos , Dor Crônica/sangue , Imunoglobulinas/sangue , Dor Pélvica/sangue , Prostatite/sangue , Adulto , Estudos de Casos e Controles , Doença Crônica , Dor Crônica/classificação , Voluntários Saudáveis , Humanos , Imunoglobulina A/sangue , Imunoglobulina G/sangue , Imunoglobulina M/sangue , Masculino , Dor Pélvica/classificação , Prostatite/classificação , Síndrome , Adulto Jovem
17.
Andrologia ; 50(3)2018 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-29205874

RESUMO

A mouse model was developed to simulate the clinical features of chronic prostatitis/chronic pelvic pain syndrome using peptide (T2 ). Forty C57BL/6 mice were divided into four groups of 10 mice each, averagely and randomly. T2 plus aluminium hydroxide adjuvant group was given subcutaneous injection with the emulsion mixture of T2 and aluminium hydroxide adjuvant, the T2 group with T2 , the aluminium hydroxide adjuvant group with aluminium hydroxide adjuvant and the normal control group with 0.9/% NaCl solution. Haematoxylin andeosin staining was used to observe the inflammation of the prostate. Plasma levels of TNF-α and CRP were detected by ELISA kit. The expression of IL-1ßin the prostate was investigated by immunohistochemistry. The statistical differences between the groups were compared by t test. Histopathological analyses demonstrated that prostate lesions were most severe in the group immunised with T2 plus aluminium hydroxide adjuvant. Plasma levels of TNF-α and CRP were statistically elevated compared with control groups. The expression levels of IL-1ß in the prostate were more obvious than control groups. T2 in aluminium hydroxide adjuvant subcutaneous injection could successfully set up experimental autoimmune prostatitis in C57BL/6 mice. This murine model would be greatly beneficial to further comprehend the aetiology, pathogenesis and explicit treatment of CP/CPPS.


Assuntos
Hidróxido de Alumínio , Doenças Autoimunes/induzido quimicamente , Dor Pélvica/induzido quimicamente , Prostatite/induzido quimicamente , Animais , Doenças Autoimunes/sangue , Proteína C-Reativa/metabolismo , Modelos Animais de Doenças , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Dor Pélvica/sangue , Próstata/metabolismo , Prostatite/sangue , Fator de Necrose Tumoral alfa/sangue
18.
Patol Fiziol Eksp Ter ; 61(2): 56-60, 2017.
Artigo em Russo | MEDLINE | ID: mdl-29215841

RESUMO

Objective. To study features of histamine metabolism in patients with chronic pelvic pain associated with external genital endometriosis. Methods. For quantitative assessment of histamine level in peripheral blood was taken from 100 patients which than was centrifuged. In blood serum histamine concentration was determined by enzyme-linked immunosorbent assay method with reagents «Histamine ЕLISA¼ on the machine BAE-1000 Histamine (Labor Diagnostika Nord - LDN, Hermany). A pain syndrome was assessed by Visual Analog Scale (VAS), quality of life assessment - by Endometriosis Health Profile Questionnaire (EHR-30), level of anxiety was determined by Spielberger-Khanin questionnaire. The results. Showed statistically higher histamine level in patients with severe pain according to VAS. After assessment of results obtained from Spielberger-Khanin questionnaire 100% experimental group's women with external genital endometriosis (n = 60) were noted to be have high level of state and trait anxiety, then 40% women of control group (n = 16) have moderate level of anxiety. The incidence of depression in women with chronic pelvic pain was 58.3% (n = 35) and the main part (n = 20) were women with severe stage of pelvic pain according to VAS. Conclusions. Psycho emotional condition of women with external genital endometriosis associated pelvic pain characterized by higher depression and anxiety levels, with significant decrease quality of life. Direct relationship also was found between pain syndrome intensity and histamine level in peripheral blood in patients with external genital endometriosis.


Assuntos
Ansiedade/sangue , Dor Crônica/sangue , Endometriose/sangue , Histamina/sangue , Dor Pélvica/sangue , Adolescente , Adulto , Ansiedade/psicologia , Dor Crônica/psicologia , Endometriose/psicologia , Feminino , Humanos , Dor Pélvica/psicologia
19.
Fertil Steril ; 108(6): 1016-1025.e2, 2017 12.
Artigo em Inglês | MEDLINE | ID: mdl-29202955

RESUMO

OBJECTIVE: To investigate the usefulness of soluble galectin-9 (Gal-9) in the noninvasive laboratory diagnosis of endometriosis and various gynecologic disorders. DESIGN: Prospective case-control study. SETTING: University medical centers. PATIENT(S): A total of 135 women of reproductive age were involved in the study, 77 endometriosis patients, 28 gynecologic controls, and 30 healthy women. INTERVENTION(S): Diagnostic laparoscopy and collection of tissue biopsies, peritoneal cells, and native peripheral blood from different case groups of gynecology patients and healthy women. MAIN OUTCOME MEASURE(S): The expression of mRNA and serum concentration of Gal-9. RESULT(S): Semiquantitative reverse transcription-polymerase chain reaction analysis and serum soluble Gal-9 ELISA were performed on three different cohorts of patients: those with endometriosis, those with benign gynecologic disorders, and healthy controls. Differences in the Gal-9 concentrations between the investigated groups and the stability of Gal-9 in the serum and diagnostic characteristics of Gal-9 ELISA were determined by statistical evaluation and receiver operating characteristic (ROC) curve analysis. Significantly elevated Gal-9 levels were found in both minimal-mild (I-II) and moderate-severe (III-IV) stages of endometriosis in comparison with healthy controls. At a cutoff of 132 pg/mL, ROC analysis revealed an excellent diagnostic value of Gal-9 ELISA in endometriosis (area under the curve = 0.973) with a sensitivity of 94% and specificity of 93.75%, indicating better diagnostic potential than that of other endometriosis biomarkers. Furthermore, various pelvic pain or infertility-associated benign gynecologic conditions were also associated with increased serum Gal-9 levels. CONCLUSION(S): Our results suggest that Gal-9 could be a promising noninvasive biomarker of endometriosis and a predictor of various infertility or pelvic pain-related gynecologic disorders.


Assuntos
Endometriose/sangue , Galectinas/sangue , Infertilidade Feminina/sangue , Dor Pélvica/sangue , Adulto , Área Sob a Curva , Biomarcadores/sangue , Estudos de Casos e Controles , Endometriose/complicações , Endometriose/diagnóstico , Endometriose/genética , Ensaio de Imunoadsorção Enzimática , Feminino , Galectinas/genética , Humanos , Infertilidade Feminina/diagnóstico , Infertilidade Feminina/etiologia , Infertilidade Feminina/genética , Pessoa de Meia-Idade , Dor Pélvica/diagnóstico , Dor Pélvica/etiologia , Dor Pélvica/genética , Valor Preditivo dos Testes , Estudos Prospectivos , RNA Mensageiro/genética , Curva ROC , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Fatores de Risco , Índice de Gravidade de Doença , Regulação para Cima
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA